Preferences help
enabled [disable] Abstract
Number of results
2018 | 102 | 47-58
Article title

The effectiveness of patent foramen ovale closure and antiplatelet or anticoagulant therapies for cryptogenic ischemic stroke

Title variants
Languages of publication
Patent foramen ovale (PFO) occurs in approximately 50% cryptogenic strokes cases. One of the most clinically important consequences of PFO is paradoxical embolization of venous thrombus resulting in recurrent stroke. The aim of this meta-analysis is to compare the efficacy and safety of PFO closure and antiplatelet or anticoagulant therapy alone (medical therapy, MT) in the secondary stroke prevention. Eligible studies for meta-analysis published from May 2008 to May 2018 were identified through a search of PubMed database and two clinical trial registries websites: and EU Clinical Trials Register. A meta-analysis was conducted with the use of Statistica software version 13.1. Three studies comprising 2’307 patients were included. The main outcomes were: recurrent stroke occurrence during follow-up period, the frequency of serious adverse events (SAE) and the mortality rate. Statistical significance was found in the assessment of recurrent stroke occurrence when the comparison referred to PFO closure and antiplatelet therapy (RR 0,30, p < 0,05, 95% CI 0,11 – 0,85). There were no significant differences between PFO closure and MT in the frequency of SAE occurrence (RR 1,03, p = 0,73) and mortality rates (RR 0,69, p = 0,39). Current clinical data indicate that PFO closure devices applied to the carefully selected group of young and middle-aged patients with cryptogenic ischemic stroke may be as or more effective than antiplatelet therapy.
Physical description
  • Chair and Department of Neurology, Medical University of Lublin, Poland
  • Chair and Department of Neurology, Medical University of Lublin, Poland
  • Chair and Department of Neurology, Medical University of Lublin, Poland
  • Department of Cancer Genetics with Cytogenetics Laboratory, Medical University of Lublin, Poland
  • Chair and Department of Neurology, Medical University of Lublin, Poland
  • Chair and Department of Neurology, Medical University of Lublin, Poland
  • [1] J.L. Saver, H.P. Mattle, D. Thaler, Patent Foramen Ovale Closure Versus Medical Therapy for Cryptogenic Ischemic Stroke. A Topical Review. Stroke 49 (2018) doi: 10.1161/STROKEAHA.117.018153.
  • [2] R.G. Hart, H.C. Diener, S.B. Coutts, J.D. Easton, C.B. Granger, M.J. O’Donnell, R.L. Sacco, S.J. Connolly, for the Cryptogenic Stroke/ESUS International Working Group, Embolic strokes of undetermined source: the case for a new clinical construct. The Lancet Neurology 13 (2014) 429–438.
  • [3] E.J. Benjamin, S.S. Virani, C.W. Callaway, A.M. Chamberlain, A.R. Chang, S. Cheng, S.E. Chiuve, M. Cushman, F.N. Delling, R. Deo, et al., American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee, Heart Disease and Stroke Statistics-2018 Update: A Report From the American Heart Association. Circulation 137 (2018) 67-492
  • [4] S. Homma, S.R. Messé, T. Rundek, Y.-P. Sun, J. Franke, K. Davidson, H. Sievert, R.L. Sacco, M.R. Di Tullio, Patent foramen ovale. Nature Reviews Disease Primers volume 2 (2016) doi:10.1038/nrdp.2015.86
  • [5] J. Neill, C.H. Lin, A Review of Transcatheter Closure of Patent Foramen Ovale. Methodist DeBakey Cardiovascular Journal 13 (2017) 152-159.
  • [6] D.M. Wiktor, J.D. Carroll. The Case for Selective Patent Foramen Ovale Closure After Cryptogenic Stroke. Circulation. Cardiovascular Interventions 11 (2018).
  • [7] D. Moher, A. Liberati, J.Tetzlaff, D.G. Altman, The PRISMA Group (2009), Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Medicine (2009) e1000097. doi:10.1371/journal.pmed1000097
  • [8] J.L. Mas, G. Derumeaux, B. Guillon, E. Massardier, H. Hosseini, L. Mechtouff, C. Arquizan, Y. Béjot, F. Vuillier, O. Detante, et al, CLOSE Investigators, Patent Foramen Ovale Closure or Anticoagulation vs. Antiplatelets after Stroke. The New England Journal of Medicine 377 (2017) 1011-1021.
  • [9] J.L. Saver, J.D. Carroll, D.E. Thaler, R.W. Smalling, L.A. MacDonald, D.S. Marks, D.L Tirschwell, RESPECT Investigators, Long-Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke. The New England Journal of Medicine 377 (2017) 1022-1032.
  • [10] L. Søndergaard, S.E. Kasner, J.F. Rhodes, G. Andersen, H.K. Iversen, J.E. Nielsen-Kudsk, M. Settergren, C. Sjöstrand, T.O. Roine, D. Hildick-Smith, et al., REDUCE Clinical Study Investigators, Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke. The New England Journal of Medicine 377 (2017) 1033-1042.
  • [11] A.J. Furlan, M. Reisman, J. Massaro, L. Mauri, H. Adams, G.W. Albers, R. Felberg, H. Herrmann, S. Kar, M. Landzberg, A. Raizner, L. Wechsler, CLOSURE I Investigators, Closure or medical therapy for cryptogenic stroke with patent foramen ovale. The New England Journal of Medicine 366 (2012) 991-999.
  • [12] J.D Carroll, J.L. Saver, D.E. Thaler, R.W. Smalling, S. Berry, L.A. MacDonald, D.S. Marks, D.L. Tirschwell, RESPECT Investigators, Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. The New England Journal of Medicine 368 (2013) 1092-1100.
  • [13] B. Meier, B. Kalesan, H.P. Mattle, A.A. Khattab, D. Hildick-Smith, D. Dudek, G. Andersen, R. Ibrahim, G. Schuler, A.S. Walton, A. Wahl, S. Windecker, P. Jüni, PC Trial Investigators, Percutaneous closure of patent foramen ovale in cryptogenic embolism. The New England Journal of Medicine 368 (2013) 1083-1091.
  • [14] W.J. Powers, A.A. Rabinstein, T. Ackerson, O.M. Adeoye, N.C. Bambakidis, K. Becker, J. Biller, M. Brown, B.M. Demaerschalk, B. Hoh, et al., 2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke 49 (2018) 46-99.
  • [15] P. Kirchhof, S, Benussi, D. Kotecha, A. Ahlsson, D. Atar, B. Casadei, M. Castella, H.C. Diener, H. Heidbuchel, J. Hendriks, et al., 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace 18 (2016) 1609–1678.
  • [16] J.L. Mas, C. Arquizan, C. Lamy, M. Zuber, L. Cabanes, G. Derumeaux, J. Coste, Patent Foramen Ovale and Atrial Septal Aneurysm Study Group, Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. The New England Journal of Medicine 345 (2001) 1740-1746.
  • [17] C.G. Favilla, E. Ingala, J. Jara, E. Fessler, B. Cucchiara, S.R. Messé, M.T. Mullen, A. Prasad, J. Siegler, M.D. Hutchinson, S.E. Kasner, Predictors of finding occult atrial fibrillation after cryptogenic stroke. Stroke 46 (2015) 1210-1215.
Document Type
Publication order reference
YADDA identifier
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.